The availability of molecular genetic testing has critically influenced the approach to diagnosing rare and ultrarare conditions such as VPS13A disease and XK disease (previously known as chorea-acanthocytosis and McLeod syndrome, respectively) as well as Cohen syndrome (due to VPS13B mutations). This evidence concerns the gene VPS13A and chorea-acanthocytosis.